PRESS RELEASE: Heidelberg Pharma Receives Milestone Payment from Partner Magenta (1130805)

 
 DGAP-News: Heidelberg Pharma AG / Key word(s): Alliance 
Heidelberg Pharma Receives Milestone Payment from Partner Magenta 
 
2020-09-14 / 07:16 
The issuer is solely responsible for the content of this announcement. 
 
*PRESS RELEASE* 
 
*Heidelberg Pharma Receives Milestone Payment from Partner Magenta * 
 
*Ladenburg, Germany, 14 September 2020 -* Heidelberg Pharma AG (FSE: HPHA) 
announced today that it has received a milestone payment from its 
cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta) 
(NASDAQ: MGTA) associated with the initiation of the GLP toxicology study 
for the development candidate MGTA-117. 
 
Prof. Andreas Pahl, CSO of Heidelberg Pharma AG, commented: "We are 
delighted that Magenta is advancing the program forward toward clinical 
trials for MGTA-117. MGTA-117, an antibody amanitin conjugate based on our 
ATAC technology, is intended to be developed for the targeted conditioning 
of patients undergoing stem cell transplants due to blood cancer or genetic 
diseases." 
 
*About Magenta Therapeutics* 
Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage 
biotechnology company developing novel medicines for patients with 
autoimmune diseases, blood cancers and genetic diseases. By creating a 
platform focused on critical areas of unmet need, Magenta Therapeutics is 
pioneering an integrated approach to allow more patients to receive 
one-time, curative immune reset. 
 
*About Heidelberg Pharma's proprietary ATAC technology* 
Antibody drug conjugates (ADCs) combine the high affinity and specificity of 
antibodies with the potency of cytotoxic small molecules for the treatment 
of cancer. Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose 
active ingredient is made up of amatoxin molecules. Amatoxins are small 
bicyclic peptides naturally occurring in the death cap mushroom. They 
inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that 
is crucial for the survival of eukaryotic cells. In preclinical testing, 
ATACs have been shown to be highly efficacious, overcoming frequently 
encountered resistance mechanisms and combating even quiescent tumor cells. 
 
*About Heidelberg Pharma * 
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, 
Germany. Heidelberg Pharma is an oncology specialist and the first company 
to develop the toxin Amanitin into cancer therapies. The proprietary 
technology platform is being applied to develop the Company's proprietary 
therapeutic ATACs as well as in third-party collaborations. The proprietary 
lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. Heidelberg 
Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN 
A11QVV / Symbol HPHA. More information is available at 
www.heidelberg-pharma.com [1]. 
 
*Contact*                            *IR/PR support* 
Heidelberg Pharma AG                 MC Services AG 
Sylvia Wimmer                        Katja Arnold (CIRO) 
Tel.: +49 89 41 31 38-29             Managing Director & 
Email: investors[at]hdpharma.com     Partner 
Gregor-Mendel-Str. 22, 68526         Tel.: +49 89 210 228-40 
Ladenburg                            Email: 
                                     katja.arnold[at]mc-service 
                                     s.eu 
 
This communication contains certain forward-looking statements relating to 
the Company's business, which can be identified by the use of 
forward-looking terminology such as "estimates", "believes", "expects", 
"may", "will" "should" "future", "potential" or similar expressions or by a 
general discussion of the Company's strategy, plans or intentions. Such 
forward-looking statements involve known and unknown risks, uncertainties 
and other factors, which may cause our actual results of operations, 
financial condition, performance, or achievements, or industry results, to 
be materially different from any future results, performance or achievements 
expressed or implied by such forward-looking statements. Given these 
uncertainties, prospective investors and partners are cautioned not to place 
undue reliance on such forward-looking statements. We disclaim any 
obligation to update any such forward-looking statements to reflect future 
events or developments. 
 
2020-09-14 Dissemination of a Corporate News, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:    English 
Company:     Heidelberg Pharma AG 
             Gregor-Mendel-Str. 22 
             68526 Ladenburg 
             Germany 
Phone:       +49 (0)89 41 31 38 - 0 
Fax:         +49 (0)89 41 31 38 - 99 
E-mail:      investors@hdpharma.com 
Internet:    www.heidelberg-pharma.com 
ISIN:        DE000A11QVV0 
WKN:         A11QVV 
Listed:      Regulated Market in Frankfurt (Prime Standard); Regulated 
             Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, 
             Tradegate Exchange 
EQS News ID: 1130805 
 
End of News DGAP News Service 
 
1130805 2020-09-14 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=06f89067b06acaccb40a39e7529a5cea&application_id=1130805&site_id=vwd&application_name=news
(END) Dow Jones Newswires
September 14, 2020 01:16 ET (05:16 GMT)
Wilex (LSE:0QW5)
過去株価チャート
から 12 2024 まで 1 2025